Effectiveness of pegylated erythropoietin in renal anaemia patients on dialysis-a multicentre, cross-sectional, observational outcome study

E. Mahesh; C. M. Thiagarajan; Mahendra M. Mulani; Mukesh M. Shete; Krishna V. Patil; K. Sravan Kumar; Babu Francis; Shriniwas M. Ambike; Kanai Lal Karmakar; Shashi Kumar; Javed M. Vakil; Sanjay Rampure; Ashok Kumar Panda; N. Venkatesh; Ajay Goyal; V. Dhanalakshmi; Amit Pasari; Manish R. Balwani; Manish Kumar Singla

doi:10.18203/2320-6012.ijrms20232411

Authors

E. Mahesh Ramaiah Memorial Hospital, Bangalore, Karnataka, India
C. M. Thiagarajan Fortis Malar Hospital, Chennai, Tamil Nadu, India
Mahendra M. Mulani Aadhya Women's and Kidney Hospital, Ahmedabad, Gujarat, India
Mukesh M. Shete Kimaya Kidney Care, Mumbai, Maharashtra, India
Krishna V. Patil Sunshine Hospital, Hyderabad, Telangana, India
K. Sravan Kumar Varma Hospital, Bhimavaram, Andhra Pradesh, India
Babu Francis Lisie Hospital, Kochi, Kerala, India
Shriniwas M. Ambike Jehangir Hospital, Pune, Maharashtra, India
Kanai Lal Karmakar RG Kar Medical College and Hospital, Kolkata, West Bengal, India
Shashi Kumar Paras HMRI Hospital, Patna, Bihar, India
Javed M. Vakil Vakil Kidney Care, Ahmedabad, Gujarat, India
Sanjay Rampure Malathi Manipal Hospital, Bangalore, Karnataka, India
Ashok Kumar Panda Care Hospital, Bhubaneswar, Odisha, India
N. Venkatesh Annai Arul Hospital, Chennai, Tamil Nadu, India
Ajay Goyal Kidney Care Centre, Panchkula, Haryana, India
V. Dhanalakshmi Virinchi Hospital, Hyderabad, Telangana, India
Amit Pasari Saraswati Kidney Care Hospital, Nagpur, Maharashtra, India
Manish R. Balwani Saraswati Kidney Care Hospital, Nagpur, Maharashtra, India
Manish Kumar Singla Max Super Speciality Hospital, Mohali, Punjab, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20232411

Keywords:

PegEPO, Anaemia, CKD, Dialysis, Outcome

Abstract

Background: Low dose of pegylated erythropoietin (PegEPO) is better than conventional erythropoietin stimulating agents (ESAs) in improving hyporesponsiveness and maintaining stable haemoglobin (Hb) levels in renal anaemic patients undergoing hemodialysis. This real-world study aimed to assess effectiveness and safety of low-dose PegEPO (30 µg/0.3 mL), administered at different time-points in renal anaemia patients on dialysis.

Methods: HEMEPEG (HEMoglobin outcomE with PegEPO) was a multicentre, retrospective, cross-sectional, observational study of renal anaemia patients receiving PegEPO up to 3 months. The study assessed an increase in Hb, patients achieving Hb 10-12 g/dl, and Hb increase by ≥1 and ≥2 g/dl.

Results: Data from 223 out of 273 patients from 19 Indian centers were analyzed. PegEPO was administered weekly to 132 patients (59.19%), with 38.64% being diabetic and 77.27% previously treated with ESAs. Ten day dosing was given to 91 patients (40.81%), including 46.15% diabetic patients and 72.53% previously treated with ESAs. A Significant (p<0.0001) increase in mean Hb levels from baseline to day 30, 60 and 90 were observed for both studied groups, with a target Hb of 10-12 g/dl achieved in 51.08% and 52.85% of patients in the respective groups after 3 months. An increase in Hb by ≥1 and ≥2 g/dl were observed in weekly (68.67% and 45.78%) and 10-day group (77.14% and 50.00%) patients, respectively.

Conclusions: PegEPO (30 µg/0.3 mL) was effective treatment of renal anaemia and diabetic chronic kidney disease (CKD) patients on dialysis when administered weekly or every 10 days over a 3-month treatment period.

Metrics

Metrics Loading ...

References

Babitt JL and Lin HY. Mechanisms of Anemia in CKD. J Am Soc Nephrol. 2012;23:1631-4.

Portolés J, Martín L, Broseta JJ. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med. 2021;8.

Martínez-Castelao A, Cases A, Coll E. C.E.R.A. administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2015;35:80-86.

Hayat A, Haria D and Salifu MO. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. Patient Prefer Adherence. 2008;2:195-200.

Gafter-Gvili A, Schechter A and Rozen-Zvi B. Iron Deficiency Anemia in Chronic Kidney Disease. Acta Haematologica. 2019;142:44-50.

Cheng HW, Chan KY, Lau HT. Use of Erythropoietin-Stimulating Agents (ESA) in Patients With End-Stage Renal Failure Decided to Forego Dialysis: Palliative Perspective. Am J Hospice Palliative Care. 2017;34:380-84.

Mimura I, Tanaka T and Nangaku M. How the Target Hemoglobin of Renal Anemia Should Be? Nephron 2015;131:202-9.

Drüeke TB and Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 2012;82:952-60.

Locatelli F, Covic A, Eckardt K-U. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dialysis Transplantation. 2008;24:348-54.

Macdougall I. CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4:436-40.

El-Komy MH, Widness JA and Veng-Pedersen P. Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology. Drug Metab Dispos. 2011;39:603-9.

Frimat L, Mariat C, Landais P. Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialyses), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis. BMJ Open. 2013;3.

Heidenreich S, Leistikow F, Zinn S. Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study. Clin Drug Investigation. 2012;32:99-110.

Minutolo R, Zamboli P, Chiodini P. Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients. Blood Purification. 2010;30:186-94.

MIRCERA (methoxy polyethylene glycol-epoetin beta). Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125164s078lbl.pdf. Accessed on 12 March, 2023.

Levin NW, Fishbane S, Cañedo FV. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet (London, England). 2007;370:1415-21.

Kawai Y, Toya Y, Wakui H. Comparison of the effects of weekly and biweekly intravenous CERA administration on erythropoiesis: A randomized controlled trial. Journal of clinical hypertension (Greenwich, Conn). 2021;23:870-78.

Erypeg® Prescribing Information. Intas Pharmaceuticals Limited. 2021.

Mehta KD. On Behalf of ERYPEG Study Group. Comparative clinical efficacy and safety of erypeg®; a biosimilar of pegylated erythropoietin (pegepo) in the treatment of adult patients with anaemia of ckd who were not on dialysis. Poster Presentation. Indian J Nephrol. 2016;26(S2):52-136.

Central Drugs Standard Control Organisation (CDSCO). r-DNA based drugs approved in country. Intas Pharmaceuticals Limited. Peg-EPO. MF-84/2015 BULK-83/2015. Available at https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadBiologicalrDNA/rdnaform46.pdf. Accessed on on 12 March, 2023.

Bhatt A. Conducting real-world evidence studies in India. Perspect Clin Res. 2019;10:51-6.

Sulowicz W, Locatelli F, Ryckelynck JP. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Society Nephrol. 2007;2:637-46.

Nand N, Nandan R and Jain D. Comparative Effects of Pegylated Erythropoietin and Darbepoetin Alfa on Erythropoietin Hyporesponsive Anemia of Patients with Chronic Kidney Disease on Maintenance Hemodialysis. J Asso Physicians of India. 2021;69:62-5.

Trotta F, Belleudi V, Fusco D. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy. BMJ Open. 2017;7:e011637.

Toida T, Sato Y, Shibata N. A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients. Blood Purification. 2014;38:174-9.

Morikami Y, Fujimori A, Okada S. Twice-monthly administration of a lower dose of epoetin beta pegol can maintain adequate hemoglobin levels in hemodialysis patients. Therapeutic Apheresis Dialysis. 2015;19:138-43.

Kakimoto-Shino M, Toya Y, Kuji T. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Therapeutic Apheresis Dialysis. 2014;18:421-6.

Nainan GK, Pathak VR, Dalal SS. A single arm, prospective, open label, multicentre study for evaluation of efficacy and safety of IV CERA for treatment of chronic renal anaemia in dialysis patients not currently treated with ESA. J Asso Physicians India. 2014;62:232-6.

Vankar SG, Dutta P, Kohli HS. Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis. Indian J Med Res. 2014;139:112-6.

Canaud B, Mingardi G, Braun J. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dialysis Transplantation. 2008;23:3654-61.

Astor BC, Muntner P, Levin A. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Internal Med. 2002;162:1401-8.